Show simple item record

dc.contributor.authorLim, Sok Bee
dc.contributor.authorBanerjee, Amrita
dc.contributor.authorÖnyüksel, Hayat
dc.date.accessioned2013-12-05T19:17:42Z
dc.date.available2013-12-05T19:17:42Z
dc.date.issued2012-10
dc.identifier.bibliographicCitationLim SB, Banerjee A, Önyüksel H. Improvement of drug safety by the use of lipid-based nanocarriers. J Control Release. 2012 Oct 10;163(1):34-45. doi: 10.1016/j.jconrel.2012.06.002.en_US
dc.identifier.issn1873-4995
dc.identifier.urihttp://hdl.handle.net/10027/10822
dc.descriptionNOTICE: This is the author’s version of a work that was accepted for publication in Journal of Controlled Release. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Journal of Controlled Release, [Vol 163, Issue 1, 2012] DOI: 10.1016/j.jconrel.2012.06.002en_US
dc.description.abstractDrug toxicity is an important factor that contributes significantly to adverse drug events in current healthcare practice. Application of lipid-based nanocarriers in drug formulation is one approach to improve drug safety. Lipid-based delivery systems include micelles, liposomes, solid lipid nanoparticles, nanoemulsions and nanosuspensions. These carriers are generally composed of physiological lipids well tolerated by human body. Delivery of water-insoluble drugs in these formulations increases their solubility and stability in aqueous media and eliminates the need for toxic co-solvents or pH adjustment to solubilize hydrophobic drugs. Association or encapsulation of peptides/proteins within lipid-based carriers protects the labile biologics against enzymatic degradation, hence reducing the therapeutic dose required and risk of dose-dependent toxicity. Most importantly, lipid-based nanocarriers alter the pharmacokinetics and biodistribution of drugs through passive and active targeting, leading to increased drug accumulation at target sites while significantly decreasing non-specific distribution to other tissues. Furthermore, surface modification of these nanocarriers reduces immunogenicity of drug-carrier complexes, imparts stealth by preventing opsonization and removal by phagocytes and minimizes interaction with circulating blood components. In view of heightening attention on drug safety in patient treatment, lipid-based nanocarrier is therefore an important and promising option for formulation of pharmaceutical products to improve treatment safety and efficacy.en_US
dc.language.isoen_USen_US
dc.publisherElsevieren_US
dc.subjectLipid nanocarriersen_US
dc.subjectdrug safetyen_US
dc.subjectmicellesen_US
dc.subjectliposomesen_US
dc.titleImprovement of drug safety by the use of lipid-based nanocarriersen_US
dc.typeArticleen_US


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record